window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : November 16, 2025

  • News
  • About Us
Contact Us

gastroenterology

  • Chronic diseases,Clinical Development,Clinical studies,Clinical Trials,Pharmaceuticals and therapeutics,Research & Development

    Amorphical reports positive interim results from ongoing Crohn’s disease trial

    Amorphical, developer of nano-amorphous mineral-based pharmacologic agents, has announced positive [...]

    October 1, 2025
  • Artificial Intelligence,Clinical Development,Global health,Medical devices,Partnerships & Funding

    Magentiq Eye secures Series A funding to advance AI-powered colonoscopy solutions

    Investment led by aMoon will support US and EU commercialisation [...]

    August 1, 2025
  • Artificial Intelligence,Clinical Trials,Drug Development,Real world evidence,Research & Development

    QuantHealth clinical trial simulations deliver $31.4m savings and 90% accuracy

    QuantHealth has simulated more than 350 clinical trials using its [...]

    July 23, 2025
  • Biologics & Biosimilars,Clinical Development,Patient Centricity,Regulatory Affairs

    NICE recommends Mirikizumab for moderately to severely active Crohn’s Disease after biologic failure

    Mirikizumab is now recommended by NICE for routine NHS use [...]

    July 14, 2025
  • Clinical Trials,Drug Development,Patient Centricity,Regulatory Affairs

    NICE backs mirikizumab for treatment-resistant Crohn’s disease

    The National Institute for Health and Care Excellence (NICE) has [...]

    May 30, 2025

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2025 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Clairity raises $43 million to launch FDA-authorized AI platform for breast cancer risk prediction
    Categories: Artificial Intelligence, Biotech, Clinical Development, Diagnostics, Digital Health, Drug Development, Global health, Healthcare leadership, Precision medicine, Women's Health
  • FDA approves Kura and Kyowa Kirin’s ziftomenib for relapsed or refractory AML
    Categories: Drug approval, Oncology, Pharmaceuticals and therapeutics
  • Successful treatment for ALS could deliver billions in global value
    Categories: Neurosciences, Rare Diseases, Research & Development
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top